Liquid Biopsy Market Is Estimated To Witness High Growth Owing To Detection Of Circulating Tumor Cells

Liquid Biopsy Market
Liquid Biopsy Market 


The Liquid Biopsy Market is estimated to be valued at Us$ 13,220 Mn in 2022 and is expected to exhibit a CAGR Of 4.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:

Liquid biopsy is a non-invasive blood test for detecting various types of cancer in the body. It allows doctors to obtain sample of tumor DNA circulating in the bloodstream. This technology is useful for monitoring cancer progression, detecting recurrence and determining the best treatment options. It provides safer and cost-effective alternative to surgical biopsy.

Market Dynamics:


Rising adoption for non-invasive detection of cancer is a major driver of growth for the liquid biopsy market. Liquid biopsies offer a seamless alternative to surgical tissue biopsies, which are more complex and invasive procedures. Additionally, ongoing advancements in liquid biopsy technologies such as newly developed assays, next-generation sequencing, and rapid detection kits are also fueling market growth. Researchers are using liquid biopsies to identify new biomarkers and develop new therapies, thus increasing the clinical applications of liquid biopsy.


Market key trends:

One of the major trend fueling the growth of liquid biopsy market is its ability to detect circulating tumor cells (CTCs). CTCs are tumor cells that shed from primary tumor sites and circulate through blood. Detection of CTCs is considered as one of the promising approach for early cancer screening and metastasis monitoring. Liquid biopsy can detect the presence of CTCs using technologies like PCR, immunoaffinity capture and microfluidics. This allows physicians to identify cancers at early stages and monitor therapeutic responses. Researchers are also exploring new approaches like isolation and characterization of CTCs to gain more insights about metastatic cancer and develop new treatments. Advancements in CTC detection technologies using liquid biopsy are expected to drive significant market growth over the forecast period.


Key Takeaways

The global Liquid Biopsy Market is expected to witness high growth, exhibiting a CAGR of 4.5% over the forecast period, due to increasing prevalence of cancer cases globally.

North America dominated the global market in 2022 and is expected to continue its dominance over the forecast period. This is attributed to increasing healthcare expenditure and presence of advanced healthcare infrastructure in the region. Asia Pacific is expected to exhibit fastest growth over the forecast period owing to growing initiatives by public and private organizations to spread awareness about early cancer detection.

The global liquid biopsy market size was valued at US$ 13,220.0 Mn in 2022. The market size is projected to reach US$ 20,432.9 Mn by 2028.

Key players operating in the liquid biopsy market are Guardant Health, F. Hoffmann-La Roche Ltd, Exact Sciences Corporation, Myriad Genetics, Bio-Rad Laboratories Inc., Qiagen N.V., Menarini Silicon Biosystems, Thermo Fisher Scientific Inc., Illumina Inc. and MDxHealth SA.

Read More :  https://www.newswirestats.com/the-liquid-biopsy-market-poised-for-strong-growth-on-back-of-technological-advancements/

Comments

Popular posts from this blog

The Global Railway Connectors Market Growth Accelerated By Growing Urban Rail Network

Global Space Robotic Solution Market is Estimated To Witness High Growth Owing to Increasing Government Initiatives and Advancements in Robotics Technology

The High Speed Engine Market Is Estimated To Witness High Growth Owing To Rising Demand For Fuel Efficient Engines